TY - JOUR
T1 - Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset Cerebellar Ataxia
AU - Pellerin, David
AU - Danzi, Matt C.
AU - Wilke, Carlo
AU - Renaud, Mathilde
AU - Fazal, Sarah
AU - Dicaire, Marie Josée
AU - Scriba, Carolin K.
AU - Ashton, Catherine
AU - Yanick, Christopher
AU - Beijer, Danique
AU - Rebelo, Adriana
AU - Rocca, Clarissa
AU - Jaunmuktane, Zane
AU - Sonnen, Joshua A.
AU - Larivière, Roxanne
AU - Genís, David
AU - Molina Porcel, Laura
AU - Choquet, Karine
AU - Sakalla, Rawan
AU - Provost, Sylvie
AU - Robertson, Rebecca
AU - Allard-Chamard, Xavier
AU - Tétreault, Martine
AU - Reiling, Sarah J.
AU - Nagy, Sara
AU - Nishadham, Vikas
AU - Purushottam, Meera
AU - Vengalil, Seena
AU - Bardhan, Mainak
AU - Nalini, Atchayaram
AU - Chen, Zhongbo
AU - Mathieu, Jean
AU - Massie, Rami
AU - Chalk, Colin H.
AU - Lafontaine, Anne Louise
AU - Evoy, François
AU - Rioux, Marie France
AU - Ragoussis, Jiannis
AU - Boycott, Kym M.
AU - Dubé, Marie Pierre
AU - Duquette, Antoine
AU - Houlden, Henry
AU - Ravenscroft, Gianina
AU - Laing, Nigel G.
AU - Lamont, Phillipa J.
AU - Saporta, Mario A.
AU - Schüle, Rebecca
AU - Schöls, Ludger
AU - La Piana, Roberta
AU - Synofzik, Matthis
AU - Zuchner, Stephan
AU - Brais, Bernard
N1 - Funding Information:
Supported by the Fondation Groupe Monaco ; a grant (PT79418) from the Montreal General Hospital Foundation ; a grant (192497) from the Canadian Institutes of Health Research ( CIHR ); the Care4Rare Canada Consortium, which is funded in part by Genome Canada and the Ontario Genomics Institute ( OGI -147), the Canadian Institutes of Health Research, Ontario Research Fund , Genome Quebec , and the Children’s Hospital of Eastern Ontario Foundation ; a grant (2R01NS072248-11A1, to Dr. Zuchner) from the National Institutes of Neurological Disorders and Stroke , National Institutes of Health; a Genome Canada Genome Technology Platform award (to Dr. Ragoussis); Canada Foundation for Innovation CGEn (to Dr. Ragoussis); the European Joint Program on Rare Diseases (EJP RD), under the EJP RD COFUND-EJP no. 825575 as part of the PROSPAX consortium, which is funded by the German Research Foundation (to Drs. Synofzik and Schüle); by the Clinician Scientist program PRECISE.net, which is funded by Else Kröner-Fresenius-Stiftung ; by the Solve-RD project, which is funded from European Union Horizon 2020 research and innovation program under grant agreement 779257; a grant (01GM1905, to Dr. Schüle) from the Federal Ministry of Education and Research , Germany, through the TreatHSP network; and a grant (2007681, to Dr. Laing) from the Medical Research Future Fund Genomics Future Health Mission . Dr. Pellerin holds a Fellowship award from the CIHR and a Detweiler Travelling Fellowship from the Royal College of Physicians and Surgeons of Canada. Dr. Wilke received support from the Clinician Scientist Program of the Faculty of Medicine, University of Tübingen (grant 480-0-0). Dr. Renaud received a Preston-Robb postdoctoral research fellowship from the Montreal Neurological Hospital and Institute. Ms. Scriba is supported by an Australian Government Research Training Program Scholarship and the Australasian Genomic Technologies Association Ph.D. top-up award. Dr. Jaunmuktane is supported by the Department of Health National Institute for Health and Care Research Biomedical Research Centre funding scheme to University College London Hospitals (UCLH). Dr. Choquet received doctoral awards from the Fonds de Recherche du Québec–Santé and the Fondation du Grand Défi Pierre Lavoie. Dr. Tétreault is supported by a Junior 1 Research Award from the Fonds de Recherche du Québec–Santé. Dr. Boycott is supported by a CIHR Foundation grant (FDN-154279) and a Tier 1 Canada Research Chair in Rare Disease Precision Health. Dr. Dubé holds the Canada Research Chair in precision medicine data analysis. Dr. Houlden is supported by the Wellcome Trust, the U.K. Medical Research Council, and the UCLH Biomedical Research Centre. Dr. Ravenscroft is funded by an Australian National Health and Medical Research Council (NHMRC) Emerging Leader Investigator Grant (APP2007769). Dr. Laing received support from NHMRC fellowship APP1117510. Dr. La Piana received funds from the Canadian Radiological Society. Drs. Schüle, Schöls, and Synofzik are members of the European Reference Network for Rare Neurological Diseases (project 739510).
Publisher Copyright:
© 2022 Massachusetts Medical Society.
PY - 2023
Y1 - 2023
N2 - Background: The late-onset cerebellar ataxias (LOCAs) have largely resisted molecular diagnosis. Methods: We sequenced the genomes of six persons with autosomal dominant LOCA who were members of three French Canadian families and identified a candidate pathogenic repeat expansion. We then tested for association between the repeat expansion and disease in two independent case-control series - one French Canadian (66 patients and 209 controls) and the other German (228 patients and 199 controls). We also genotyped the repeat in 20 Australian and 31 Indian index patients. We assayed gene and protein expression in two postmortem cerebellum specimens and two induced pluripotent stem-cell (iPSC)-derived motor-neuron cell lines. Results: In the six French Canadian patients, we identified a GAA repeat expansion deep in the first intron of FGF14, which encodes fibroblast growth factor 14. Cosegregation of the repeat expansion with disease in the families supported a pathogenic threshold of at least 250 GAA repeats ([GAA]≥250). There was significant association between FGF14 (GAA)≥250 expansions and LOCA in the French Canadian series (odds ratio, 105.60; 95% confidence interval [CI], 31.09 to 334.20; P<0.001) and in the German series (odds ratio, 8.76; 95% CI, 3.45 to 20.84; P<0.001). The repeat expansion was present in 61%, 18%, 15%, and 10% of French Canadian, German, Australian, and Indian index patients, respectively. In total, we identified 128 patients with LOCA who carried an FGF14 (GAA)≥250 expansion. Postmortem cerebellum specimens and iPSC-derived motor neurons from patients showed reduced expression of FGF14 RNA and protein. Conclusions: A dominantly inherited deep intronic GAA repeat expansion in FGF14 was found to be associated with LOCA.
AB - Background: The late-onset cerebellar ataxias (LOCAs) have largely resisted molecular diagnosis. Methods: We sequenced the genomes of six persons with autosomal dominant LOCA who were members of three French Canadian families and identified a candidate pathogenic repeat expansion. We then tested for association between the repeat expansion and disease in two independent case-control series - one French Canadian (66 patients and 209 controls) and the other German (228 patients and 199 controls). We also genotyped the repeat in 20 Australian and 31 Indian index patients. We assayed gene and protein expression in two postmortem cerebellum specimens and two induced pluripotent stem-cell (iPSC)-derived motor-neuron cell lines. Results: In the six French Canadian patients, we identified a GAA repeat expansion deep in the first intron of FGF14, which encodes fibroblast growth factor 14. Cosegregation of the repeat expansion with disease in the families supported a pathogenic threshold of at least 250 GAA repeats ([GAA]≥250). There was significant association between FGF14 (GAA)≥250 expansions and LOCA in the French Canadian series (odds ratio, 105.60; 95% confidence interval [CI], 31.09 to 334.20; P<0.001) and in the German series (odds ratio, 8.76; 95% CI, 3.45 to 20.84; P<0.001). The repeat expansion was present in 61%, 18%, 15%, and 10% of French Canadian, German, Australian, and Indian index patients, respectively. In total, we identified 128 patients with LOCA who carried an FGF14 (GAA)≥250 expansion. Postmortem cerebellum specimens and iPSC-derived motor neurons from patients showed reduced expression of FGF14 RNA and protein. Conclusions: A dominantly inherited deep intronic GAA repeat expansion in FGF14 was found to be associated with LOCA.
KW - Genetics
KW - Genetics General
KW - Neurology/Neurosurgery
KW - Neurology/Neurosurgery General
KW - Neuromuscular Disease
KW - Neuroscience
UR - http://www.scopus.com/inward/record.url?scp=85149203656&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa2207406
DO - 10.1056/NEJMoa2207406
M3 - Article
C2 - 36516086
AN - SCOPUS:85149203656
SN - 0028-4793
VL - 388
SP - 128
EP - 141
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 2
ER -